The combination of GLP-1R-mediated appetite suppression, GIPR-mediated adipose tissue metabolism, and GCGR-driven energy expenditure makes it one of the most comprehensive research tools for studying multi-pathway obesity biology in a single compound
Ozempic maker Novo Nordisk wrote to AHPRA and the Pharmacy Board of Australia almost a year ago outlining its concerns about compounded semaglutide, given it requires very advanced laboratory techniques
A quick calculation
While nuts do have a lot of protein by weight, theyre extremely high in calories and not ideal for increasing protein intake
Frequently Asked Questions Is Nausea Normal On GLP-1s
The pivotal Phase 2 trial a 48-week study published in The New England Journal of Medicine in 2023 produced these results in adults with obesity (and no diabetes), at the highest dose of 12 mg weekly: Average weight loss of around 24% from baseline A clear dose-response, with even the 4 mg dose producing roughly 17% weight loss Continued weight loss right up to the 48-week endpoint, with no plateau in sight For context, similar Phase 2 data for Wegovy showed around 15% weight loss at 68 weeks
.png)
